

INDEPENDENT RESEARCH

Healthcare

21st October 2016

Haemophilia: « Stemming the bleed »

Healthcare

SHIRE PLC	BUY	FV 6900p
Bloomberg SHP LN	Reuters SHP.L	
Price 5176p	High/Low 5323/3480p	
Market cap. GBP46,738m	Enterprise Val GBP61,711M	
PE (2016e) 15.0x	EV/EBIT (2016e) 17.1x	
GRIFOLS	NEUTRAL	FV EUR20
Bloomberg GRF SM	Reuters GRF.MC	
Price EUR18,625	High/Low EUR22,7375/18	
Market Cap. EUR11,509m	Enterprise Val 1EUR5,083m	
PE (2016e) 21.6x	EV/EBIT (2016e) 15.5x	
SOBI	SELL	FV SEK90
Bloomberg SOBI SS	Reuters SOBIV.ST	
Price CHF101,3	High/Low CHF139,3/95,85	
Market Cap. CHF27,391m	Enterprise Val 28,557	
PE (2016e) 46.2x	EV/EBIT (2016e) 33.2x	
NOVO NORDISK	NEUTRAL	DKK355
Bloomberg NOVOB.CO	Reuters NOVOB.CO	
Price 270,5DKK	High/Low 404,2/265,7	
Market Cap. 544 399 MDKK	Enterprise Val 518 987 MDKK	
PE (2016e) 17,4x	EV/EBIT (2016e) 10,4x	
ROCHE	ACHAT	CHF293
Bloomberg ROG VX	Reuters ROG.VX	
Price 235,8CHF	High/Low 279,3/233,2	
Market Cap. 165 664 MCHF	Enterprise Val 178 330 MCHF	
PE (2016e) 14,9x	EV/EBIT (2016e) 9,1x	

The haemophilia market has attracted particular investor attention in recent months. Our sector report aims notably to help investors better assess the challenges/issues in this very specific and ultimately fairly unknown market.


■ We estimate that the majority of the haemophilia market, and more precisely, patients without inhibiting antibodies, will remain widely addressed by substitution therapies based on coagulation factors. On the other hand, Approaches such as ACE910 and Fitusiran are clearly set to provide an advantage. However, we believe they are primarily set to address haemophilia A patients with inhibiting antibodies, for whom the medical need is the most important.


■ **Shire is still one of our top picks** as we believe that 1/ its commercial and clinical portfolio should help it continue to outperform peers (Grifols, SOBI or even CSL) in haemophilia A; and 2/ we estimate that the group should be capable of maintaining growth momentum following the arrival of Roche's ACE910 and Alnylam's Fitusiran.

■ **Roche is the second name that stands out on our radar.** Admittedly, the share's performance remains above all dependent on the results of the APHINITY study. However, we estimate the group's portfolio includes a number of projects for which revenues could easily approach the USD2bn mark and ACE910 is clearly one of them in our view.

■ Whereas the consensus has more than factored in the pressure caused by the arrival of ACE910 on Feiba's sales at Shire, we estimate that **forecasts are overly optimistic for NovoSeven by Novo Nordisk.**

■ We are initiating coverage of **Grifols with a Neutral recommendation and a FV of EUR20**, and coverage of **SOBI with a Sell recommendation and a FV of SEK90.**



	Analyst:	Sector Analyst Team:
	Mickael Chane Du	Eric Le Berrigaud
	33(0) 1 70 36 57 45	Hugo Solvet
	mchanedu@bryangarnier.com	Marion Levi